By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Citing a market shift toward the MiSeq desktop sequencer, Goldman Sachs today revised its earnings per share estimates for Illumina.

For 2011, the investment bank maintained EPS estimates at $1.55, but lowered its forecast for 2012 to $2.04 from $2.08, and its estimate for 2013 to $2.64 from $2.70. It also cut its 12-month share price target to $83 from $84.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.

Apr
15
Sponsored by
WaferGen

This live online seminar will highlight recent trends in applying next-generation sequencing in the clinical setting, with a particular focus on oncology and rare disease.